Latest Decheng Capital LLC Stock Portfolio
Decheng Capital LLC Performance:
2025 Q1: -11.67%YTD: -11.67%2024: 29.27%
Performance for 2025 Q1 is -11.67%, and YTD is -11.67%, and 2024 is 29.27%.
About Decheng Capital LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Decheng Capital LLC reported an equity portfolio of $356.5 Millions as of 31 Mar, 2025.
The top stock holdings of Decheng Capital LLC are , NUVB, . The fund has invested 43.8% of it's portfolio in CG ONCOLOGY INC and 12.8% of portfolio in NUVATION BIO INC.
The fund managers got completely rid off PHATHOM PHARMACEUTICALS INC (PHAT) and ATRICURE INC. (ATRC) stocks. They significantly reduced their stock positions in VERA THERAPEUTICS INC (VERA), ILLUMNIA, INC. (ILMN) and BIONTECH SE-ADR. Decheng Capital LLC opened new stock positions in AARDVARK THERAPEUTICS INC. The fund showed a lot of confidence in some stocks as they added substantially to ACLARIS THERAPEUTICS, INC. (ACRS) and CRINETICS PHARMACEUTICALS IN (CRNX).
The top stock holdings of Decheng Capital LLC are , NUVB, . The fund has invested 43.8% of it's portfolio in CG ONCOLOGY INC and 12.8% of portfolio in NUVATION BIO INC.
The fund managers got completely rid off PHATHOM PHARMACEUTICALS INC (PHAT) and ATRICURE INC. (ATRC) stocks. They significantly reduced their stock positions in VERA THERAPEUTICS INC (VERA), ILLUMNIA, INC. (ILMN) and BIONTECH SE-ADR. Decheng Capital LLC opened new stock positions in AARDVARK THERAPEUTICS INC. The fund showed a lot of confidence in some stocks as they added substantially to ACLARIS THERAPEUTICS, INC. (ACRS) and CRINETICS PHARMACEUTICALS IN (CRNX).
Decheng Capital LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Decheng Capital LLC made a return of -11.67% in the last quarter. In trailing 12 months, it's portfolio return was -24.89%.
New Buys
| Ticker | $ Bought |
|---|---|
| aardvark therapeutics inc | 29,418,900 |
New stocks bought by Decheng Capital LLC
Additions
| Ticker | % Inc. |
|---|---|
| aclaris therapeutics, inc. | 78.31 |
| crinetics pharmaceuticals in | 5.95 |
Additions to existing portfolio by Decheng Capital LLC
Reductions
| Ticker | % Reduced |
|---|---|
| vera therapeutics inc | -90.97 |
| illumnia, inc. | -87.6 |
| biontech se-adr | -50.00 |
| arcellx inc | -40.74 |
| legend biotech corp-adr | -34.88 |
| 4d molecular therapeutics in | -16.12 |
| krystal biotech inc | -15.33 |
| zentalis pharmaceuticals inc. | -13.62 |
Decheng Capital LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| phathom pharmaceuticals inc | -5,637,340 |
| atricure inc. | -818,916 |
Decheng Capital LLC got rid off the above stocks
Sector Distribution
Decheng Capital LLC has about 63% of it's holdings in Others sector.
| Sector | % |
|---|---|
| Others | 63 |
| Healthcare | 37 |
Market Cap. Distribution
Decheng Capital LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 67.5 |
| SMALL-CAP | 17.6 |
| MID-CAP | 11.5 |
| MICRO-CAP | 2.7 |
Stocks belong to which Index?
About 29.5% of the stocks held by Decheng Capital LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 70.3 |
| RUSSELL 2000 | 29.5 |
Decheng Capital LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Decheng Capital LLC
Decheng Capital LLC has 27 stocks in it's portfolio. About 86.5% of the portfolio is in top 10 stocks. NUVB proved to be the most loss making stock for the portfolio. KRYS was the most profitable stock for Decheng Capital LLC last quarter.
Last Reported on: 08 May, 2025| Ticker | Namesorted descending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| cg oncology inc | 43.77 | 6,371,670 | 156,042,000 | unchanged | 0.00 | |||
| NUVB | nuvation bio inc. | 12.81 | 25,954,400 | 45,679,800 | unchanged | 0.00 | ||
| aardvark therapeutics inc | 8.25 | 3,917,300 | 29,418,900 | new | ||||
| upstream bio inc. | 5.64 | 3,285,290 | 20,106,000 | unchanged | 0.00 | |||
| NAMS | newamsterdam pharma co nv | 4.42 | 770,000 | 15,761,900 | unchanged | 0.00 | ||
| KRYS | krystal biotech inc | 3.29 | 65,000 | 11,719,500 | reduced | -15.33 | ||
| RVMD | revolution medicines inc(nsm) | 2.24 | 226,000 | 7,991,360 | unchanged | 0.00 | ||
| MRUS | merus nv | 2.23 | 189,098 | 7,959,140 | unchanged | 0.00 | ||
| BYSI | beyondspring inc. | 1.96 | 4,882,650 | 6,971,600 | unchanged | 0.00 | ||
| moonlake immunotherapeutics | 1.88 | 171,600 | 6,704,410 | unchanged | 0.00 | |||
| LYEL | lyell immunopharma, inc. | 1.80 | 11,909,300 | 6,407,220 | unchanged | 0.00 | ||
| RCUS | arcus biosciences, inc | 1.78 | 808,789 | 6,348,990 | unchanged | 0.00 | ||
| ACRS | aclaris therapeutics, inc. | 1.74 | 4,041,740 | 6,183,860 | added | 78.31 | ||
| CRNX | crinetics pharmaceuticals in | 1.67 | 177,958 | 5,968,710 | added | 5.95 | ||
| CYTK | cytokinetics inc | 1.13 | 100,000 | 4,019,000 | unchanged | 0.00 | ||
| legend biotech corp-adr | 0.95 | 100,000 | 3,393,000 | reduced | -34.88 | |||
| ACLX | arcellx inc | 0.92 | 50,000 | 3,280,000 | reduced | -40.74 | ||
| ZNTL | zentalis pharmaceuticals inc. | 0.90 | 2,019,760 | 3,211,420 | reduced | -13.62 | ||
| AURA | aura biosciences, inc. | 0.85 | 515,555 | 3,021,150 | unchanged | 0.00 | ||
| biontech se-adr | 0.51 | 20,000 | 1,821,200 | reduced | -50.00 | |||
